MedTrace Logo

Demodex Blepharitis Treatment Study

NCT01647217 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-07-26

Study results available
· View outcomes & findings →

Summary

This is a randomized clinical trial to determine the safety and efficacy of terpinen-4-ol (T4O), the most active ingredient of tea tree oil (TTO), in eradicating ocular demodicosis (reducing ocular demodex counts and achieving the clinical improvement with minimal or no irritation).

Conditions

  • Chronic Blepharitis

Interventions

DRUG

Terpinen-4-ol

Lid scrub once or twice per day for one month.

OTHER

Placebo

Lid scrub once or twice per day for one month

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • BioTissue Holdings, Inc

    lead INDUSTRY

Principal Investigators

  • Scheffer CG Tseng, MD, PhD · BioTissue Holdings, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-06-30
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01647217 on ClinicalTrials.gov